GB05

GB05 is a nebulized formulation of recombinant human interferon alpha-1b (IFNα1b) developed as an inhalation therapy primarily for the treatment of respiratory syncytial virus (RSV) infection. Interferon alpha-1b is a type I interferon cytokine that stimulates the immune response by binding to the interferon-alpha/beta receptor (IFNAR), leading to antiviral and immunomodulatory effects. GB05 has been evaluated in phase 1 clinical trials for safety, tolerability, and pharmacokinetics in healthy adults and is being further investigated in pediatric populations with RSV infection. The drug demonstrates favorable lung uptake with low systemic exposure when administered via nebulization[1][3][4]. It was developed under FDA guidelines and has received approval for clinical trials targeting pediatric RSV infections[2].

Brand names

Yundesu

Other names

human interferon alpha-1b inhalation solutionIFNα1b inhalation solutionrecombinant human interferon α1b inhalation solution